StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review

Reuters
02/11
StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review

StenoCare A/S has submitted a full regulatory dossier for its ASTRUM 10-10 oil product to French medical authorities as part of the national process to evaluate medical cannabis for potential reimbursement following France's 2021-2025 pilot programme. The submission was made in partnership with the Institut des Cannabinoïdes Médicaux Français (ICMF). The regulatory review by the Haute Autorité de Santé $(HAS)$ is a key step in determining whether and under what conditions medical cannabis treatments may be reimbursed in France. Movianto, a leading French pharmaceutical distributor, will handle nationwide logistics and pharmacy supply if approval is granted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: BITN____20260210BIT9015) on February 11, 2026, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10